Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Molecular Pathways in the Hypothalamus Lead to Hypertension and Cardiovascular Disease

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Print article
A recent paper linked overexpression of mTORC1 (mammalian target of rapamycin complex 1) activity in the hypothalamus to the development of cardiovascular diseases.

MTORC1 is a serine/threonine protein kinase of the phosphatidylinositol 3-kinase (PI3K) protein family that regulates cell growth, proliferation, motility, survival, protein synthesis, and transcription. In cancer cells, the mTOR pathway is deregulated and signals tumor cells to grow, divide, and metastasize.

Investigators at the University of Iowa (Iowa City, USA) showed in the April 2, 2013, issue of the journal Cell Metabolism that mTOR signaling in the hypothalamus was tied to the activity of the sympathetic nervous system and to cardiovascular function.

Modulation of mTORC1 signaling caused dramatic changes in sympathetic traffic, blood flow, and arterial pressure. The data also demonstrated the importance of hypothalamic mTORC1 signaling in transducing the sympathetic and cardiovascular actions of leptin, a hormone produced by fat cells that has been implicated in obesity-related hypertension. Leptin activated mTORC1 in a specific part of the hypothalamus causing increased nerve activity and a rise in blood pressure. These effects were blocked by inhibiting activation of mTORC1.

"Our study shows that when this protein [mTORC1] is either activated or inhibited in a very specific manner, it can cause dramatic changes in blood pressure,” said senior author Dr. Kamal Rahmouni, associate professor of pharmacology and internal medicine at the University of Iowa. "Given the importance of this protein for the control of blood pressure, any abnormality in its activity might explain the hypertension associated with certain conditions like obesity and cardiovascular disease."

"Cardiovascular diseases are the leading cause of death worldwide, and hypertension is a major cardiovascular risk factor," said Dr. Rahmouni. "Our study identifies the protein called mTORC1 in the hypothalamus as a key player in the control of blood pressure. Targeting mTORC1 pathways may, therefore, be a promising strategy for the management of cardiovascular risk factors."

Related Links:

University of Iowa



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.